血清长链非编码RNAMALAT-1在卵巢癌诊断中的临床意义  

The Effects of Serum-based Long Non-coding RNA MALAT-1 Detection in Diagnosing Ovarian Cancer

作　　者：李星[1] 刘玉杰[1] 张艺凡[1] 姚玲[1] 高原[1] 惠宁[1] 

机构地区：[1]解放军第二军医大学附属长海医院妇产科,上海200433

出　　处：《现代生物医学进展》2016年第27期5254-5257,共4页Progress in Modern Biomedicine

基　　金：上海市科委科研基金项目(20113140)

摘　　要：目的:探讨血清长链非编码RNA MALAT-1检测在卵巢癌患者中的诊断作用。方法:收集187例在我院行卵巢肿瘤切除术患者术前血清。应用实时定量PCR检测血清中MALAT-1 m RNA的表达。MALAT-1 m RNA的拷贝数使用绝对定量(标准曲线)计算。MALAT-1的诊断价值采用ROC-AUC曲线和logistic回归分析并与血清CA125进行比较。结果:1本研究有效样本比例为88.77%(166/187)。卵巢良性肿瘤和恶性肿瘤比例分别为62.05%(103/166)和37.95%(63/166)。卵巢恶性肿瘤患者MALAT-1明显高于良性肿瘤患者(p<0.001)。经ROC曲线分析,血清CA125和MALAT-1曲线下面积分别为0.726和0.844,且血清MALAT-1的诊断价值明显优于血清CA125(p=0.023)。经logistic回归分析,应用血清MALAT-1和CA125的预测准确性分别为78.92%和68.07%,应用血清MALAT-1可提高预测准确性10.85%。进一步的分析得出,取血清MALAT-1截断点为36.5时,其预测的敏感性和特异性分别高达84.1%和67.0%。结论:血清长链非编码RNA MALAT-1检测对卵巢肿瘤的性质具有良好的预测作用,可作为卵巢癌早期诊断的分子标志物。本研究结果需大样本前瞻性的研究进一步验证。Objective： To evaluate the diagnostic power of serum-based long non-coding RNA MALAT-1 detection to ovarian cancer. Methods： Serum was collected from 187 women before ovarian tumor resection. The expression of serum MALAT-1 m RNA was determined by quantitative real time polymerase chain reaction（q RT-PCR）. The MALAT-1 copies were calculated using a standard curve. The ability of the MALAT-1 to predict the tumor outcome was assessed with an AUC-ROC analysis and logistic regression. Then,the diagnostic power of serum MALAT-1 was compared with the serum CA125 levels. Results： The informative specimen rate was88.77%（166/187）. The rates of benign tumor and ovarian cancer were 62.05%（103/166） and 37.95%（63/166）, respectively. The copies of serum MALAT-1 were significantly higher in patients with ovarian cancers than in those with benign ones（P〈0.001）. The ROC curve analysis demonstrated that the area under the ROC curve（AUC） of serum CA125 and MALAT-1 was 0.726 and 0.844, respectively. Further analysis revealed that serum MALAT-1 was much better than CA125 to diagnosing ovarian cancer（p=0.023）. The logistic regression analysis demonstrated that the predictive accuracy was increased by 10.85%, by using serum MALAT-1（78.92%）, compared to CA125（68.07%）. Further analysis showed that its sensitivity and specificity were as high as 84.1% and 67.0% respectively when taking 36.5 as the cutoff site of serum MALAT-1. Conclusions： Serum MALAt-1 was found to be a good predictor of ovarian cancer before surgery and it can be a useful serum-based biomarker to diagnose ovarian cancer. Further large-scale prospective studies are needed to confirm our findings.

关 键 词：MALAT-1 卵巢癌 血清 分子标志物 

分 类 号：R737.31[医药卫生—肿瘤]